Equilibrating the Effects of Gravity-Gradient Potential on the Orbits of Lorentz Triaxial Spacecraft
Symmetry · 26.03.2026 · 18 (4) · 567
DOI: 10.3390/sym18040567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Symmetry, online erschienen am 26.03.2026. Verfasst von M. A. Yousef. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Abdulaziz University.
Abstract (Originalsprache)
In this paper, the effects of gravity-gradient potential on a spacecraft of arbitrary shape are outlined. The potential expressing the planet’s gravity-gradient torque on a triaxial spacecraft is formed. The planet’s shape is considered oblate spheroidal, and the dimensions of the spacecraft are assumed small compared to its distance from the center of the planet. The radial, transverse and normal components of the Lorentz force, in terms of orbital elements, are constructed. The variations in the orbital elements due to both gravity-gradient potential and Lorentz force are derived. The charges per unit mass needed to balance such perturbation are obtained. The symmetrical results in mathematical equations are obvious. The International Space Station (ISS) is used as an example to test our model. A three-dimensional diagram was plotted to illustrate the charge per unit mass with the shape and size of the orbits.
Förderung
- King Abdulaziz University
Zitieren
APA
Yousef, M. A. (2026). Equilibrating the Effects of Gravity-Gradient Potential on the Orbits of Lorentz Triaxial Spacecraft. Symmetry, 18(4), 567. https://doi.org/10.3390/sym18040567
Vancouver
Yousef MA. Equilibrating the Effects of Gravity-Gradient Potential on the Orbits of Lorentz Triaxial Spacecraft. Symmetry. 2026;18(4):567. doi:10.3390/sym18040567
BibTeX
@article{Yousef2026,
author = {Yousef, M. A.},
title = {Equilibrating the Effects of Gravity-Gradient Potential on the Orbits of Lorentz Triaxial Spacecraft},
journal = {Symmetry},
year = {2026},
volume = {18},
number = {4},
pages = {567},
doi = {10.3390/sym18040567}
}
EUVIMED